


IS AMYLOIDOSIS ROOTED IN YOUR FAMILY?



Know *Your* Amyloidosis

Learn More About Familial Amyloidotic Polyneuropathy (FAP)

Amyloidosis is a group of diseases in which the body accumulates deposits of abnormal proteins known as amyloid in organs or organ systems. One form of familial amyloidosis is caused by a mutation in the transthyretin (TTR) gene, resulting in abnormal TTR protein production. Familial Amyloidotic Polyneuropathy (FAP) occurs when the TTR amyloid deposition is in the peripheral nervous system, while Familial Amyloidotic Cardiomyopathy (FAC) occurs when the deposition is in the heart.


FAP and FAC remain significantly under-diagnosed and have limited treatment options.

This booklet provides information about FAP screening options and possible next steps for people who wish to learn more about the disease. It is important to understand which type of amyloidosis you have, so you can learn about your treatment options and get the best possible care.

Learn more about FAP at www.alnylam.com/FAP

FAP Symptoms

Patients with FAP experience the following symptoms



*Suanprasert N, et al. J Neurol Sci 2014

Alnylam Pharmaceuticals is committed to advancing the diagnosis and treatment of Familial Amyloidotic Polyneuropathy (FAP). As part of our commitment, Alnylam is now sponsoring free third party screening for patients who may carry a genetic mutation known to be associated with FAP.

If you or a family member may have FAP, learn more about the Alnylam Assist™ program. Call [1.866.330.0326](tel:1.866.330.0326) to find a participating physician near you.

Alnylam  Assist™

Available only in the US.



Currently, limited treatment options are available for patients with FAP. Consult your doctor to discuss which options may be right for you.


Some patients may choose to participate in a clinical trial.

Learn about clinical trials at www.clinicaltrials.gov

WHAT IS A CLINICAL TRIAL AND WHO CAN PARTICIPATE?

A clinical trial involves research using human volunteers (trial participants), and is intended to add to medical knowledge. Results can make a difference in the care of future patients by providing information about the benefits and risks of therapeutic interventions. Clinical trials have standards outlining who can participate, which are outlined in a research plan or protocol. Certain factors such as age, gender, or stage of the disease, could allow or disqualify participation in a clinical trial (referred to as inclusion and exclusion criteria).

TOP REASONS PEOPLE CHOOSE TO PARTICIPATE IN CLINICAL TRIALS



Source: CISCRP, 2013; N=5,701 people worldwide / www.ciscrp.org

WHAT ARE THE BENEFITS AND RISKS OF PARTICIPATING IN A CLINICAL TRIAL?

Possible Benefits:

- Play an active role in your health
- Be considered for access to investigational therapies
- Help others by contributing to medical research

Possible Risks:

- Possible unknown or serious treatment side effects
- Lack of benefit or positive clinical outcome for participant
- Increased time commitments for study visits

WHERE CAN I LEARN MORE ABOUT CLINICAL TRIALS?

Go to www.clinicaltrials.gov for information on eligibility to participate in a study, risks and benefits of study participation, the informed consent process, questions to ask when considering whether to participate in a study, and much more information.

1



Contact Your Doctor

FAP is a rare disease. Not all doctors have experience with FAP patients. You may need to see a specialist who can further discuss diagnostic and treatment options with you.

2



Your Family and FAP

Because FAP is an inherited disease, your family's medical history will be important information to provide to your doctor. You may want to talk with your family to find out if any relatives have experienced symptoms consistent with FAP.

3



Learn More About FAP

Visit www.alnylam.com/FAP

To receive e-mail alerts with more information about FAP, join Alnylam's Patient Connect.

Sign-up at www.alnylam.com/patients/patient-connect-aln-ttr/



ALNYLAM'S
COMMITMENT TO
FAP

Alnylam is a biopharmaceutical company developing a new class of innovative medicines. We have a core focus on investigating therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients.

Learn more at www.alnylam.com





Learn more at www.аныlam.com